SUBSCRIBE
SUBSCRIBE

Anavex Life Sciences Corp.

NEWS
TRICON: Clinical Exome Sequencing More Efficient and Unbiased, Says Pathologist
Drug Development
TRICON: Alzheimer’s Drug Saw 80% Reversal in Memory Loss, Say Anavex CEO
February 18, 2015
 · 
2 min read
Load More
JOBS
IN THE PRESS
Press Releases
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
May 2, 2025
 · 
5 min read
Press Releases
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference
April 30, 2025
 · 
3 min read
Press Releases
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
April 23, 2025
 · 
5 min read
Press Releases
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East
April 21, 2025
 · 
4 min read
Press Releases
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
April 7, 2025
 · 
10 min read
Press Releases
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
April 1, 2025
 · 
3 min read
Press Releases
Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference
February 24, 2025
 · 
3 min read
Press Releases
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
February 12, 2025
 · 
7 min read
Press Releases
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025
February 5, 2025
 · 
3 min read
Press Releases
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
January 27, 2025
 · 
5 min read
Load More